BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chuntova P, Chow F, Watchmaker PB, Galvez M, Heimberger AB, Newell EW, Diaz A, DePinho RA, Li MO, Wherry EJ, Mitchell D, Terabe M, Wainwright DA, Berzofsky JA, Herold-Mende C, Heath JR, Lim M, Margolin KA, Chiocca EA, Kasahara N, Ellingson BM, Brown CE, Chen Y, Fecci PE, Reardon DA, Dunn GP, Liau LM, Costello JF, Wick W, Cloughesy T, Timmer WC, Wen PY, Prins RM, Platten M, Okada H. Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro Oncol 2021;23:356-75. [PMID: 33367885 DOI: 10.1093/neuonc/noaa277] [Cited by in Crossref: 8] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Luo H, Ye M, Hu Y, Wu M, Cheng M, Zhu X, Huang K. DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in glioma. Aging (Albany NY) 2022;14. [PMID: 36152044 DOI: 10.18632/aging.204291] [Reference Citation Analysis]
2 Sansone G, Vivori N, Vivori C, Di Stefano AL, Picca A. Basic premises: searching for new targets and strategies in diffuse gliomas. Clin Transl Imaging. [DOI: 10.1007/s40336-022-00507-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Fekrirad Z, Barzegar Behrooz A, Ghaemi S, Khosrojerdi A, Zarepour A, Zarrabi A, Arefian E, Ghavami S. Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy. Cancers 2022;14:3698. [DOI: 10.3390/cancers14153698] [Reference Citation Analysis]
4 Habashy KJ, Mansour R, Moussalem C, Sawaya R, Massaad MJ. Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them. Br J Cancer. [DOI: 10.1038/s41416-022-01864-w] [Reference Citation Analysis]
5 Chuntova P, Yamamichi A, Chen T, Narayanaswamy R, Ronseaux S, Hudson C, Tron AE, Hyer ML, Montoya M, Mende AL, Nejo T, Downey KM, Diebold D, Lu M, Nicolay B, Okada H. Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma. J Immunother Cancer 2022;10:e004644. [PMID: 35606087 DOI: 10.1136/jitc-2022-004644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Della Pepa GM, Menna G. In Reply to the Letter to the Editor Regarding "5-Aminolevulinic Acid False Positives in Cerebral Neuro-Oncology: Not All That Is Fluorescent Is Tumor. A Case-Based Update and Literature Review". World Neurosurg 2022;161:218-9. [PMID: 35505534 DOI: 10.1016/j.wneu.2022.02.050] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Gatto L, Di Nunno V, Franceschi E, Tosoni A, Bartolini S, Brandes AA. Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date? Drugs 2022. [PMID: 35397073 DOI: 10.1007/s40265-022-01702-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
8 Zhu X, Shi G, Lu J, Qian X, Wang D. Potential regulatory mechanism of TNF-α/TNFR1/ANXA1 in glioma cells and its role in glioma cell proliferation. Open Life Sciences 2022;17:208-20. [DOI: 10.1515/biol-2022-0023] [Reference Citation Analysis]
9 Yi K, Cui X, Liu X, Wang Y, Zhao J, Yang S, Xu C, Yang E, Xiao M, Hong B, Fang C, Kang C, Tan Y, Wang Q. PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma. Front Immunol 2021;12:802795. [PMID: 35069587 DOI: 10.3389/fimmu.2021.802795] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Menna G, Manini I, Cesselli D, Skrap M, Olivi A, Ius T, Della Pepa GM. Immunoregulatory effects of glioma-associated stem cells on the glioblastoma peritumoral microenvironment: a differential PD-L1 expression from core to periphery? Neurosurg Focus 2022;52:E4. [PMID: 35104793 DOI: 10.3171/2021.11.FOCUS21589] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Jang B, Kim IA. Relationship between Macrophage and Radiosensitivity in Human Primary and Recurrent Glioblastoma: In Silico Analysis with Publicly Available Datasets. Biomedicines 2022;10:292. [DOI: 10.3390/biomedicines10020292] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Shi Y, Sun Y, Cheng H, Wang C. EFNB1 Acts as a Novel Prognosis Marker in Glioblastoma through Bioinformatics Methods and Experimental Validation. J Oncol 2021;2021:4701680. [PMID: 34824583 DOI: 10.1155/2021/4701680] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Singh K, Hotchkiss KM, Mohan AA, Reedy JL, Sampson JH, Khasraw M. For whom the T cells troll? Bispecific T-cell engagers in glioblastoma. J Immunother Cancer 2021;9:e003679. [PMID: 34795007 DOI: 10.1136/jitc-2021-003679] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Lee EQ. Immune checkpoint inhibitors in GBM. J Neurooncol 2021;155:1-11. [PMID: 34599480 DOI: 10.1007/s11060-021-03859-8] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
15 Ellingson BM, Wen PY, Cloughesy TF. Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies. Cancer J 2021;27:395-403. [PMID: 34570454 DOI: 10.1097/PPO.0000000000000543] [Reference Citation Analysis]
16 Singh O, Pratt D, Aldape K. Immune cell deconvolution of bulk DNA methylation data reveals an association with methylation class, key somatic alterations, and cell state in glial/glioneuronal tumors. Acta Neuropathol Commun 2021;9:148. [PMID: 34496929 DOI: 10.1186/s40478-021-01249-9] [Reference Citation Analysis]
17 Aquilanti E, Kageler L, Wen PY, Meyerson M. Telomerase as a therapeutic target in glioblastoma. Neuro Oncol 2021:noab203. [PMID: 34473298 DOI: 10.1093/neuonc/noab203] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
18 Comba A, Faisal SM, Varela ML, Hollon T, Al-Holou WN, Umemura Y, Nunez FJ, Motsch S, Castro MG, Lowenstein PR. Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications. Front Oncol 2021;11:703764. [PMID: 34422657 DOI: 10.3389/fonc.2021.703764] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
19 Najem H, Khasraw M, Heimberger AB. Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy. Cells 2021;10:2032. [PMID: 34440802 DOI: 10.3390/cells10082032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Leko V, Cafri G, Yossef R, Paria B, Hill V, Gurusamy D, Zheng Z, Gartner JJ, Prickett TD, Goff SL, Robbins P, Lu YC, Rosenberg SA. Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma. J Immunother Cancer 2021;9:e002882. [PMID: 34266885 DOI: 10.1136/jitc-2021-002882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Rominiyi O, Collis SJ. DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies. Mol Oncol 2021. [PMID: 34036721 DOI: 10.1002/1878-0261.13020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Maggs L, Cattaneo G, Dal AE, Moghaddam AS, Ferrone S. CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma. Front Neurosci 2021;15:662064. [PMID: 34113233 DOI: 10.3389/fnins.2021.662064] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
23 Sulman EP, Eisenstat DD. World Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology. Front Oncol 2021;11:659800. [PMID: 34041027 DOI: 10.3389/fonc.2021.659800] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]